A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 89
[Display Entries]
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : THW
Long Form : thyroid hormone withdrawal
No. Year Title Co-occurring Abbreviation
2021 Effect of TSH stimulation protocols on adequacy of low-iodine diet for radioiodine administration. LID, RAI, rhTSH, TSH
2021 Evaluation of SNA001, a Novel Recombinant Human Thyroid Stimulating Hormone Injection, in Patients With Differentiated Thyroid Carcinoma. DTC, rhTSH, Tg, WBS
2021 Influence of Levothyroxine With Recombinant Human Thyroid-Stimulating Hormone on Urinary Iodine Excretion Before Radioactive Iodine Administration. rhTSH
2021 Low- and high-dose radioiodine ablation for low-/intermediate-risk differentiated thyroid cancer in China: Large randomized clinical trial. DTC
2021 Recombinant human thyroid-stimulating hormone versus thyroid hormone withdrawal preparation for radioiodine ablation in differentiated thyroid cancer in children, adolescents and young adults. DTC, rhTSH
2021 The Influences of TSH Stimulation Level, Stimulated Tg Level and Tg/TSH Ratio on the Therapeutic Effect of 131I Treatment in DTC Patients. DTC, LNM, sTg, TSH
2020 Comparison of thyroid hormone withdrawal and recombinant human thyroid-stimulating hormone administration for adjuvant therapy in patients with intermediate- to high-risk differentiated thyroid cancer. DTC, eGFR, RAI, rhTSH, Tg
2020 Failure of iodine uptake in microscopic pulmonary metastases after recombinant human thyroid-stimulating hormone stimulation. TSH
2020 Recombinant human thyrotropin versus thyroid hormone withdrawal in an Asian population. QoL, WDTC
10  2019 Age, thyroglobulin levels and ATA risk stratification predict 10-year survival rate of differentiated thyroid cancer patients. ATA, DTC, Pre-ablation sTg, RAI
11  2019 Clinical outcomes of patients with T4 or N1b well-differentiated thyroid cancer after different strategies of adjuvant radioiodine therapy. DTC, RAI, RFS, WBS
12  2019 Comparison of I-131 Biokinetics after Recombinant Human TSH Stimulation and Thyroid Hormone Withdrawal Measured by External Detector in Patients with Differentiated Thyroid Cancer. DTC, rhTSH
13  2019 Low-dose radioiodine therapy for patients with intermediate- to high-risk differentiated thyroid cancer. DTC, RAI, RIT, Tg
14  2019 Mitogen-Activated Protein Kinase Pathway Inhibition for Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer: An Evolving Protocol. DTC, FTC, MAPK, PDTC, PTC, RAI, RAIR
15  2019 Variations in radioiodine ablation: decision-making after total thyroidectomy. ATA, EANM, rhTSH
16  2018 Comparison of day 3 and day 5 thyroglobulin results after thyrogen injection in differentiated thyroid cancer patients. RAI, rhTSH, Tg, TSH
17  2018 Could short thyroid hormone withdrawal be an effective strategy for radioiodine remnant ablation in differentiated thyroid cancer patients? DTC, RRA
18  2018 Do TSH, FT3, and FT4 Impact BAT Visualization of Clinical FDG-PET/CT Images? ---
19  2018 Does the use of recombinant TSH in preparation for I-131 scintigraphy scan affect hearing function? rhTSH
20  2018 Long-term outcomes of renal function after radioactive iodine therapy for thyroid cancer according to preparation method: thyroid hormone withdrawal vs. recombinant human thyrotropin. GFR, RAIT
21  2018 Radioiodine ablation in thyroid cancer patients: renal function and external radiation dose rate at discharge according to patient preparation. EDR, HD-RIT, rhTSH, Tg, TSH
22  2018 Recombinant Thyrotropin vs Levothyroxine Withdrawal in 131I Therapy of N1 Thyroid Cancer: A Large Matched Cohort Study (ThyrNod). RAI, ThyrNod
23  2018 The effect of lithium on the progression-free and overall survival in patients with metastatic differentiated thyroid cancer undergoing radioactive iodine therapy. DTC, Li, OS, PFS, RAI, rhTSH
24  2018 The minimum amount of fluids needed to achieve the fastest time to reach permissible level for release in well-differentiated thyroid patients undergoing high-dose I-131 therapy. rhTSH
25  2017 Cost-effectiveness of using recombinant human thyroid-stimulating hormone before radioiodine ablation for thyroid cancer treatment in Spanish hospitals. ICER, QALY, TSH
26  2017 I-131 biokinetics of remnant normal thyroid tissue and residual thyroid cancer in patients with differentiated thyroid cancer: comparison between recombinant human TSH administration and thyroid hormone withdrawal. mLN, ThyR, TSH, WBS
27  2017 Interrupted 131I Procedures for Patients With Differentiated Thyroid Cancer: Comparing Thyroxine Withdrawal With Recombinant Thyrotropin Preparation Techniques. rhTSH
28  2017 Preparation for radioactive iodine therapy is not a risk factor for the development of hyponatremia in thyroid cancer patients. LID, RAI
29  2017 Recombinant human TSH stimulated thyroglobulin levels at remnant ablation predict structural incomplete response to treatment in patients with differentiated thyroid cancer. ATA, NPV, RA, rhTSH, rhTSH-sTg, SIR, sTg, THW-sTg
30  2017 Recombinant human TSH versus thyroid hormone withdrawal in adjuvant therapy with radioactive iodine of patients with papillary thyroid carcinoma and clinically apparent lymph node metastases not limited to the central compartment (cN1b). RAI, rhTSH, Tg, US
31  2016 Diminished Quality of Life and Increased Brain Functional Connectivity in Patients with Hypothyroidism After Total Thyroidectomy. FC, fMRI, PHQ-9, QoL, ReHo, TH
32  2016 In Patients With Low- to Intermediate-Risk Thyroid Cancer, a Preablative Thyrotropin Level of 30 muIU/mL Is Not Adequate to Achieve Better Response to 131I Therapy. DTC, Tg
33  2016 Long-Term Outcomes of Patients with Papillary Thyroid Cancer Undergoing Remnant Ablation with 30 milliCuries Radioiodine. CI, OR
34  2016 Recombinant Human Thyroid Stimulating Hormone versus Thyroid Hormone Withdrawal for Radioactive Iodine Treatment of Differentiated Thyroid Cancer with Nodal Metastatic Disease. DTC, RAI, rhTSH
35  2016 Thyroid Hormone Withdrawal Further Exacerbates Oxidative Stress in Patients with Thyroid Carcinoma. AOPP, BMI, DTC, LHP, MPO, PCC
36  2015 Acute-on-Chronic Kidney Injury in Thyroid Hormone Withdrawal: A Case with Possible Implications for Radioactive Iodine Planning. AKI, CKD, RAI
37  2015 Age and body composition influence TSH concentrations after administration of rhTSH. BSA, DTC, LBM, RIT
38  2015 Comparative effectiveness in thyroid cancer: key questions and how to answer them. pCCND, PTC, RAI, rhTSH
39  2015 Comparison of Therapeutic Efficacy and Clinical Parameters Between Recombinant Human Thyroid Stimulating Hormone and Thyroid Hormone Withdrawal in High-Dose Radioiodine Treatment with Differentiated Thyroid Cancer. HD-RIT, rhTSH, sTg, US
40  2015 Cytogenetic dosimetry by micronucleus assay using peripheral blood cells is modified by thyroid hormones. CBMN, MN, PB
41  2015 Differences in physicians' and patients' perception of acute hypothyroid symptoms induced by thyroid hormone withdrawal in thyroid cancer patients: a multicenter survey in Korea. rhTSH
42  2015 Economic Evaluation of Recombinant Human Thyroid Stimulating Hormone Stimulation vs. Thyroid Hormone Withdrawal Prior to Radioiodine Ablation for Thyroid Cancer: The Korean Perspective. QALY, rhTSH
43  2015 Effects of recombinant human thyroid stimulating hormone on 131I therapy for the treatment of differentiated thyroid cancer. rhTSH
44  2015 Effects of Thyroid Hormone Withdrawal and Recombinant Human Thyrotropin on Glomerular Filtration Rate During Radioiodine Therapy for Well-Differentiated Thyroid Cancer. GFR, RIT
45  2015 Proprotein convertase subtilisin/kexin type 9 (PCSK9), soluble lectin-like oxidized LDL receptor 1 (sLOX-1) and ankle brachial index in patients with differentiated thyroid cancer. ABI, PCSK9, RAI, sLOX-1
46  2015 Quality of Life and Cost-Effectiveness Assessment of Radioiodine Ablation Strategies in Patients With Thyroid Cancer: Results From the Randomized Phase III ESTIMABL Trial. HRQoL, rhTSH, TSH
47  2015 Recombinant human thyroid-stimulating hormone-aided remnant ablation achieves a response to treatment comparable to that with thyroid hormone withdrawal in patients with clinically relevant lymph node metastases. LN, rhTSH
48  2015 Sensitivity of preparation with rhTSH or thyroid hormone withdrawal using I-whole body scans to identify metastases of differentiated thyroid cancer. DTC, rhTSH, Tg, WBS
49  2015 Weight Changes in Patients with Differentiated Thyroid Carcinoma during Postoperative Long-Term Follow-up under Thyroid Stimulating Hormone Suppression. BMI, DTC, RAIT, rhTSH, TSH
50  2014 A placebo-controlled, blinded and randomised study on the effects of recombinant human thyrotropin on quality of life in the treatment of thyroid cancer. DTC, QoL, RI, VAS
51  2014 Body Mass Index Is Associated with Hypercholesterolemia following Thyroid Hormone Withdrawal in Thyroidectomized Patients. ---
52  2014 Efficacy of Low-dose and High-dose Radioactive Iodine Ablation With rhTSH in Korean Patients With Differentiated Thyroid Carcinoma: The First Report in Nonwestern Countries. RAI, rhTSH, sTg
53  2014 Recombinant human thyrotropin versus thyroid hormone withdrawal in radioiodine remnant ablation for differentiated thyroid cancer: a meta-analysis. DTC
54  2014 Recombinant human thyrotropin-aided versus thyroid hormone withdrawal-aided radioiodine treatment for differentiated thyroid cancer after total thyroidectomy: a meta-analysis. DTC, QoL, RCTs, Tg
55  2014 Stimulated thyroglobulin level at ablation in differentiated thyroid cancer: the impact of treatment preparation modalities and tumor burden. DTC, PRD, rhTSH, SPECT-CT, Tg
56  2014 The effect of recombinant human thyroid stimulating hormone on sustaining liver and renal function in thyroid cancer patients during radioactive iodine therapy. ALT, AST, Cr, rhTSH, RIT
57  2014 The effectiveness of recombinant human thyroid-stimulating hormone versus thyroid hormone withdrawal prior to radioiodine remnant ablation in thyroid cancer: a meta-analysis of randomized controlled trials. rhTSH, RRA, Tg
58  2013 High-risk patients with differentiated thyroid cancer T4 primary tumors achieve remnant ablation equally well using rhTSH or thyroid hormone withdrawal. rhTSH
59  2013 Improved follow-up of patients with differentiated thyroid carcinoma. The quantitative detection limit of 131I uptake in diagnostic scans. DTC, RIU
60  2013 Stimulated thyroglobulin at recombinant human TSH-aided ablation predicts disease-free status one year later. rhTSH, Tg
61  2012 Comparison of the Influence on the Liver Function Between Thyroid Hormone Withdrawal and rh-TSH Before High-Dose Radioiodine Therapy in Patients with Well-Differentiated Thyroid Cancer. ALP, AST, rhTSH, TB, TG, TSH
62  2012 In thyroidectomized patients with thyroid cancer, a serum thyrotropin of 30 muU/mL after thyroxine withdrawal is not always adequate for detecting an elevated stimulated serum thyroglobulin. DTC, FACIT-F, Tg
63  2012 Potential use of recombinant human thyrotropin in the treatment of distant metastases in patients with differentiated thyroid cancer. DTC, RAI, rhTSH
64  2012 Radioiodine post-surgical remnant ablation in patients with differentiated thyroid cancer: news from the last 10 years. DTC, rhTSH
65  2012 Radioiodine remnant ablation in differentiated thyroid cancer after combined endogenous and exogenous TSH stimulation. DTC, RRA, TE, Tg
66  2012 Radioiodine treatment of metastatic thyroid cancer: relative efficacy and side effect profile of preparation by thyroid hormone withdrawal versus recombinant human thyrotropin. CR, DTC, HR, PD, PFS, RAI, rhTSH, SD
67  2012 Recombinant human thyroid stimulating hormone-assisted radioactive iodine remnant ablation in thyroid cancer patients at intermediate to high risk of recurrence. AJCC, ATA, rhTSH
68  2012 Recombinant human thyroid-stimulating hormone versus thyroid hormone withdrawal in the identification of metastasis in differentiated thyroid cancer with 131I planar whole-body imaging and 124I PET. DTC, rhTSH, WB
69  2012 Recombinant human thyrotropin: safety and quality of life evaluation. QoL, rhTSH
70  2012 Short-term hypothyroidism in thyroid cancer patients and cognitive-motor performance relevant for driving. DTC
71  2011 Five-year survival is similar in thyroid cancer patients with distant metastases prepared for radioactive iodine therapy with either thyroid hormone withdrawal or recombinant human TSH. RAI, rhTSH
72  2011 Iatrogenic hyperthyroidism does not promote weight loss or prevent ageing-related increases in body mass in thyroid cancer survivors. rhTSH
73  2011 Treatment room length-of-stay and patient throughput with radioiodine thyroid remnant ablation in differentiated thyroid cancer: comparison of thyroid-stimulating hormone stimulation methods. DTC, rhTSH
74  2011 [Assessment of the efficacy, safety and pharmacokinetics of SKG-02 (recombinant human TSH) in postoperative diagnosis of well-differentiated thyroid cancer--a Japanese prospective, controlled, multicenter open-label study]. AEs, AUC, Tg, tmax, WDTC
75  2010 Biokinetics of I after endogenous and exogenous stimulation of TSH in patients with DTC. rhTSH, ROIs
76  2010 Lesion dose in differentiated thyroid carcinoma metastases after rhTSH or thyroid hormone withdrawal: 124I PET/CT dosimetric comparisons. ANCOVA, DTC, IAM, rhTSH
77  2010 Radioactive iodine administered for thyroid remnant ablation following recombinant human thyroid stimulating hormone preparation also has an important adjuvant therapy function. RAI, rhTSH
78  2010 Recombinant human thyrotropin (rhTSH) aided radioiodine treatment for residual or metastatic differentiated thyroid cancer. DTC, rhTSH, TSH
79  2010 Recombinant human thyrotropin in thyroid remnant ablation with 131-iodine in high-risk patients. RA, TNM, WDTC
80  2009 Recombinant human thyroid stimulating hormone in 2008: focus on thyroid cancer management. RAI, Tg, TSH
81  2009 Salivary gland side effects commonly develop several weeks after initial radioactive iodine ablation. RAI, rhTSH, RRA
82  2009 The use of thyrogen in the treatment of differentiated thyroid carcinoma: an intraindividual comparison of clinical effects and implications of daily life. DTC, DWBS, rhTSH, Tg
83  2008 Factors related to clinical hypothyroid severity in thyroid cancer patients after thyroid hormone withdrawal. CI, DTC, OR, THST
84  2008 Length and cost of hospital stay of radioiodine ablation in thyroid cancer patients: comparison between preparation with thyroid hormone withdrawal and thyrogen. LOH, TSH
85  2008 Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal. rhTSH, RRA
86  2007 Age influences TSH serum levels after withdrawal of l-thyroxine or rhTSH stimulation in patients affected by differentiated thyroid cancer. DTC, rhTSH
87  2006 Health-related Quality of Life, depression and anxiety in thyroid cancer patients. BDI, DTC, HADS, HRQL, POMS, SF-36
88  2006 Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. rhTSH
89  2001 Preparation by recombinant human thyrotropin or thyroid hormone withdrawal are comparable for the detection of residual differentiated thyroid carcinoma. rhTSH, Tg